Abstracts tagged "proteomics and rheumatoid arthritis (RA)"

Abstract Number: 583 • 2018 ACR/ARHP Annual Meeting
Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients
Cristina Ruiz-Romero¹, Florencia Picchi², Lucia González², Rebecca Hands³, Valentina Calamia², Patricia Fernández⁴, Maria Camacho², Rocío Paz², Conrad Bessant⁵, Costantino Pitzalis³ and Francisco J Blanco⁶, ¹Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁴Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ⁵School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom, ⁶Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Among the best known disease-modifying antirheumatic drugs, Methotrexate (MTX) is one of the most effective and widely used medications. It is used as a…
Abstract Number: 1467 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Activity Monitoring and Multiplex Biomarker Verification By Tageted Proteomics
Lucía González-Rodríguez¹, Valentina Calamia¹, Patricia Fernández², Cristina Ruiz-Romero³, Antonio Julià⁴, Antonio Fernández-Nebro⁵, Jesús Tornero⁶, Sara Marsal⁴ and Francisco J Blanco³, ¹Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ³Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁴Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Spain, ⁵UGC Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Spain., Málaga, Spain, ⁶Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…
Abstract Number: 2051 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Peptide Expression By Quantitative Proteomics Delineates Responsive and Resistant Clones after Treatment of Early Rheumatoid Arthritis
Jing Jing Wang¹, William Murray-Brown², Alexander Colella¹, Malcolm D. Smith³, Tim Chataway⁴, Jenny Walker², William H. Robinson⁵, Mihir D Wechalekar² and Tom Gordon^1,6, ¹Immunology, Flinders University, Adelaide, Australia, ²Rheumatology, Flinders University, Adelaide, Australia, ³Rheumotology, Flinders University, Adelaide, Australia, ⁴Proteomic Facility, Flinders University, Adelaide, Australia, ⁵Stanford University, Palo Alto, CA, ⁶Immunology, SA Pathology, Adelaide, Australia
Background/Purpose: Rheumatoid factors (RFs) are associated with disease activity and joint damage in rheumatoid arthritis (RA) and thought to play a pathogenic role in disease.…
Abstract Number: 1019 • 2017 ACR/ARHP Annual Meeting
Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment
Victor Farutin¹, Thomas Prod'homme¹, Kevin McConnell¹, Nathaniel Washburn¹, Patrick Halvey¹, Jamey Guess¹, Nur Sibel Gunay¹, Jan Hillson², Carol J. Etzel³, Katherine C. Saunders³, Dimitrios A. Pappas^3,4, Anthony Manning¹, Leona Ling¹ and Ishan Capila¹, ¹Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, ²Clinical Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, ³Corrona, LLC, Southborough, MA, ⁴Columbia University, New York, NY
Background/Purpose: Despite the success of anti-TNF therapies in RA, ~ 30 % of patients are non-responders. Several studies have focused on understanding the biology underlying…
Abstract Number: 1358 • 2017 ACR/ARHP Annual Meeting
Relationship between Serum Protein Pattern and High Disease Activity in Patients with Rheumatoid Arthritis
Pavel Horak¹, Anna Petráčková², Martina Skácelová³, Eva Kriegová⁴, Petra Schneiderová⁵ and František Mrázek⁵, ¹III. Department of internal medicine, III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ²Department of Immunology, Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ³III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ⁴Department of Immunology,, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ⁵Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects joints. There is still limited information of serum biomarkers suitable for effective monitoring…
Abstract Number: 595 • 2015 ACR/ARHP Annual Meeting
Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab
Ignacio Ortea¹, Bernd Roschitzki², Eva Tomero³, Juan G. Ovalles-Bonilla⁴, Javier Lopez-Longo⁵, Inmaculada de la Torre⁵, Isidoro Gonzalez-Alvaro⁶, Juan J Gomez-Reino⁷ and Antonio Gonzalez⁸, ¹Maimónides Health Research Institute (IMIBIC), Cordoba, Spain, ²Functional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland, ³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Gregorio Marañon Hospital, Madrid, Spain, ⁶Hospital Univ. de La Princesa, IIS Princesa, Madrid, Spain, ⁷Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁸Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: Biomarkers of response to treatment in rheumatoid arthritis (RA) are sorely needed given the large inter-individual variability in efficacy of the available drugs. However,…
Abstract Number: 2092 • 2014 ACR/ARHP Annual Meeting
Proteomic Phenotyping of Rheumatoid Arthritis Disease Activity
Yauheniya Cherkas, Sarah Lamberth, Carrie Brodmerkel and Mark Curran, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose The use of objective biomarkers of clinical disease characteristics such as disease activity would be beneficial in informing patients, physicians and payers. Recently, a…
Abstract Number: 1691 • 2012 ACR/ARHP Annual Meeting
Early Signs of Subclinical Inflammation and Local Antibody Production in Early Rheumatoid Lungs
Gudrun Reynisdottir¹, Reza Karimi², Jimmy Ytterberg³, Vijay Joshua¹, Helga Olsen², Aase Haj Hensvold¹, Anders Harju⁴, Johan Grunewald², Sven Nyren⁵, Anders Eklund², Lars Klareskog⁶, Roman Zubarev⁷, Magnus Skold² and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁵Radiology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The aims of the current study was to investigate if inflammatory lung changes are present in RA patients early in the disease process and…
Abstract Number: 2579 • 2012 ACR/ARHP Annual Meeting
Novel Autoantibodies to 14-3-3 Eta Are Highly Specific for Rheumatoid Arthritis
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, Vivian P. Bykerk⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: Serum 14-3-3 eta, a protein biomarker that is differentially expressed in rheumatoid arthritis (RA), has been reported to add incrementally to rheumatoid factor (RF)…